- Companies
- Chr. Hansen
Chr. Hansen Acquisition & Valuation
Chr. Hansen was acquired by Novozymes for $10B in December 2022, a 7.8x multiple on $1.3B of revenue.
Chr. Hansen acquisition price
$10B
Acquired by Novozymes · Dec 2022
Chr. Hansen revenue at acquisition
$1.3B
Last twelve months · Dec 2022
Chr. Hansen revenue multiple at acquisition
7.8x
EV/Revenue · Dec 2022
Chr. Hansen EBITDA multiple at acquisition
23.6x
EV/EBITDA · Dec 2022
About Chr. Hansen
Chr. Hansen develops bioscience ingredients including bacterial cultures, enzymes, probiotics, and natural colors for food processing, beverages, dietary supplements, pharmaceuticals, and animal nutrition. Production facilities operate in Denmark, France, the United States, and Germany to serve manufacturers of dairy, meat, bakery goods, and plant-based products. Founded in 1874, the Denmark-headquartered company trades on Nasdaq Copenhagen with substantial research investments in microbial biotechnology.
Founded
1874
HQ
Website
Status
Acquired
Customer focus
B2B
Revenue model
Product sales
Revenue
$1.3B (Dec 2022)
Valuation
$10B (acquired Dec 2022)
Chr. Hansen Acquisition
Chr. Hansen was acquired by Novozymes for $10B on 12 December 2022.
The acquisition price implies a 7.8x revenue and 23.6x EBITDA multiple on $1.3B of revenue.
On 12 December 2022 Novozymes and Chr. Hansen agreed to combine through a statutory merger creating a global biosolutions group. Chr. Hansen's free float shareholders were offered 1.5326 new Novozymes B shares for each Chr. Hansen share, implying a value of DKK 660.55 per share and a premium of 49 per cent, while Novo Holdings agreed a less favourable ratio of 1.0227 for its own stake, taking the blended premium to 38 per cent. On completion Novozymes free float shareholders were to hold 44 per cent of the combined share capital, Chr. Hansen free float shareholders 34 per cent and Novo Holdings 22 per cent. The enlarged group was presented as having annual revenue of approximately EUR 3.5 billion. Chr. Hansen was a global bioscience company with more than 145 years of experience developing natural ingredients, maintaining a collection of around 40,000 microbial strains and supplying cultures, enzymes, probiotics and natural colours to the food, agriculture and pharmaceutical industries. In its financial year ended 31 August 2022 it reported revenue of EUR 1,218 million and EBIT before special items of EUR 326 million, a margin of 26.8 per cent. The merger completed in January 2024 and the combined company was renamed Novonesis.
| Acquirer | Date | Type | Price | EV/Revenue | EV/EBITDA |
|---|---|---|---|---|---|
| 12 Dec 2022 | Strategic M&A | $10B | 7.8x | 23.6x |
Sources: globenewswire.com, globenewswire.com
Chr. Hansen Funding History
Chr. Hansen has 1 recorded secondary share sale and no primary funding rounds.
| Date | Stage | Investors | Deal Summary |
|---|---|---|---|
| Mar 2012 | Secondary | Novo | In March 2012 PAI Partners sold its remaining 26 percent shareholding in Chr. Hansen to Novo A/S, a Danish holding company that invests in the life sciences sector on behalf of the Novo Nordisk Foundation. PAI had bought the food ingredients business in 2005 and floated it on the Copenhagen stock exchange in June 2010, after which it reduced its holding through the listing and two accelerated bookbuild offers. The March 2012 sale completed the exit from the investment. PAI reported that, weighted by the number of shares sold at each exit step, the realisations valued the company at about EUR 2.5 billion, against the EUR 1.1 billion paid in 2005. Chr. Hansen develops cultures, dairy enzymes and natural colours for the food, nutrition, pharmaceutical and agricultural industries. During PAI's ownership the company more than doubled its EBITDA in six years while disposing of non-core activities and expanding in emerging markets. |
Who has invested in Chr. Hansen?
1 investor has backed Chr. Hansen across its funding rounds, including Novo.
Chr. Hansen Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
This data is available for Pro users. Sign up to see all 1 Chr. Hansen investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Chr. Hansen
Chr. Hansen has acquired 3 companies to date.
Last acquisition by Chr. Hansen was on June 9th 2020. Chr. Hansen acquired UAS Laboratories for $530M.
Latest Acquisitions by Chr. Hansen
| Description | UAS Laboratories is a probiotic manufacturer specializing in formulations based on L. acidophilus DDS-1 strain. The company produces supplements for natural products retailers, health professionals, private labels, and ingredient suppliers in the US, Canada, and over 35 countries. Fully integrated operations handle formulation, manufacturing, packaging, and marketing under strict quality standards. Founded in 1979 and based in Madison, Wisconsin, UAS invests in research and production technologies for probiotic innovation. | - | Nutrition Physiology Company, LLC is a Lenexa, Kansas-based developer of livestock probiotics including BOVAMINE for cattle pathogen reduction and POULTRIMAX for poultry gut health. Products improve feed efficiency by 5 percent in trials with Kansas State University. Founded in 1993, NPC supplies to feed mills in the US and Latin America. |
| HQ Country | |||
| HQ City | Wausau, WI | - | Guymon, OK |
| Deal Date | 9 Jun 2020 | 13 Jan 2016 | 13 Jan 2016 |
| Valuation | $530M | undisclosed | $190M |
| EV/Revenue | |||
| EV/EBITDA | |||
This data is available for Pro users. Sign up to see all Chr. Hansen acquisitions and their M&A valuation multiples. Start Free Trial | |||
Chr. Hansen Competitors
Chr. Hansen competitors include listed companies like Bloomage BioTechnology, SABIC Agri-Nutrient, Industries Qatar and CF Industries, and private ones like Sangon Biotech and Colossal Biosciences.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Publicly listed | $630M | $104M | $2.5B | 4.4x | ||
| Private | $102M | - | $1.4B | 13.7x | ||
| Private | - | - | $10B | - | ||
| Publicly listed | $3.5B | $1.4B | $15B | 3.8x | ||
| Publicly listed | $4.4B | $1.6B | $17B | 5.2x | ||
| Publicly listed | $7.1B | $3.2B | $17B | 2.7x |
Chr. Hansen Public Comps
Chr. Hansen is no longer listed, but its public comps include Bio-Techne, Demant, Zhejiang NHU, 10x Genomics, SABIC Agri-Nutrient, BillionToOne, Fertiglobe, Adaptive Biotech, Cathay Biotech and Industries Qatar.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $1.2B | $343M | 9.4x | 9.2x | 33.1x | 26.1x | |||
| $3.4B | $761M | 4.3x | 3.8x | 19.4x | 15.4x | |||
| $3.3B | $1.5B | 3.5x | 3.0x | 7.6x | 6.7x | |||
| $643M | ($16M) | 11.4x | 11.6x | (452.2x) | (139.2x) | |||
| $3.5B | $1.4B | 3.4x | 3.8x | 8.5x | 11.9x | |||
| $305M | $12M | 16.5x | 11.5x | 418.2x | 71.9x | |||
| $2.8B | $1B | 2.2x | 1.8x | 6.2x | 5.4x | |||
| $277M | ($39M) | 16.8x | 15.6x | (118.3x) | 292.3x | |||
This data is available for Pro users. Sign up to see all Chr. Hansen competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Chr. Hansen
| When was Chr. Hansen founded? | Chr. Hansen was founded in 1874. |
| Where is Chr. Hansen headquartered? | Chr. Hansen is headquartered in Hørsholm, Denmark. |
| Is Chr. Hansen publicly listed? | No, Chr. Hansen was acquired by Novozymes in December 2022. |
| Who acquired Chr. Hansen? | Chr. Hansen was acquired by Novozymes in December 2022. |
| How much was Chr. Hansen acquired for? | Chr. Hansen was acquired for $10B in December 2022, a 7.8x revenue multiple. |
| Who are Chr. Hansen's investors? | Chr. Hansen's investors include Novo. |
| Which companies are comparable to Chr. Hansen? | Companies comparable to Chr. Hansen include Bloomage BioTechnology, Sangon Biotech, Colossal Biosciences, SABIC Agri-Nutrient, Industries Qatar and CF Industries. |
| How many companies has Chr. Hansen acquired? | Chr. Hansen has acquired 3 companies, including UAS Laboratories, Guardian Food Technologies LLC and Nutrition Physiology Co., LLC. |
| What was the largest acquisition by Chr. Hansen? | The $530M acquisition of UAS Laboratories in June 2020 is the largest acquisition Chr. Hansen has made to date. |
See companies similar to Chr. Hansen
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




